Cargando…
Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments
BACKGROUND: Inhaled corticosteroid/long-acting β(2)-agonist combinations and/or long-acting muscarinic antagonists are recommended first-line therapies for preventing chronic obstructive pulmonary disease (COPD) exacerbation. Comparative effectiveness of budesonide/formoterol combination (BFC, an in...
Autores principales: | Trudo, Frank, Kern, David M, Davis, Jill R, Tunceli, Ozgur, Zhou, Siting, Graham, Emma L, Strange, Charlie, Williams, Setareh A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592033/ https://www.ncbi.nlm.nih.gov/pubmed/26451101 http://dx.doi.org/10.2147/COPD.S90658 |
Ejemplares similares
-
A US database study characterizing patients initiating a budesonide–formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease
por: Kern, David M, et al.
Publicado: (2014) -
Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment
por: Davis, Jill R., et al.
Publicado: (2016) -
Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study
por: Kern, David M, et al.
Publicado: (2015) -
Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population
por: Kern, David M, et al.
Publicado: (2015) -
Efficacy and safety of tiotropium bromide combined with budesonide/formoterol in the treatment of moderate to severe chronic obstructive pulmonary disease
por: Zhao, Daguo, et al.
Publicado: (2018)